Clinical trials
Carcinoma, Hepatocellular trials in Thailand
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
45 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 2 |
| 2003 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 2 |
| 2013 | 5 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 29 |
| Terminated | 6 |
| Active, not recruiting | 5 |
| Recruiting | 2 |
| Suspended | 1 |
| Enrolling by invitation | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 5 |
| Bayer | 4 |
| Hoffmann-La Roche | 3 |
| Merck Sharp & Dohme LLC | 3 |
| Novartis Pharmaceuticals | 3 |
| Eli Lilly and Company | 2 |
| GlaxoSmithKline | 2 |
| Imunon | 2 |
| Mahidol University | 2 |
| National Cancer Centre, Singapore | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Hepatocellular | 45 |
| Liver Neoplasms | 12 |
| Neoplasms | 5 |
| Carcinoma | 3 |
| Adenocarcinoma | 1 |
| Camurati-Engelmann Syndrome | 1 |
| Digestive System Diseases | 1 |
| Digestive System Neoplasms | 1 |
| Hemorrhage | 1 |
| Hepatitis B, Chronic | 1 |
Trials
Showing 26 to 45 of 45. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.